Lubiński Wojciech, Mozolewska-Piotrowska Katarzyna, Krasodomska Kamila, Penkala Krzysztof, Kaźmierczak Beata, Karczewicz Danuta
Department of Ophthalmology, Pomeranian Medical University, Szczecin, Poland.
Klin Oczna. 2012;114(3):187-93.
To evaluate foveal function, retinal circulation and foveal thickness before and after intravitreal ranibizumab injections in eyes with wet type of age-related macular degeneration (AMD).
The study group consisted of 21 eyes (20 patients) with choroidal neovascularisation (CNV) due to AMD. Inclusion criteria were based on fluorescein angiography (FA) and distance best corrected visual acuity (DBCVA)--log MAR scale. In each eye, 3 consecutive injections of ranibizumab every 4 weeks were administered and then individual course for re-injections according to DBCVA and optical coherence tomography (OCT) up to 12 months was applied. At baseline, 3, 6 and 12 months follow-up, the following tests were performed: DBCVA, multifocal electroretinogram (mfERG) and OCT. Additionally, FA was carried out before the treatment, 3 and 12 months from the baseline.
At baseline, FA revealed mainly minimally occult choroidal neovascularisation--57% (12/21) of eyes. At 3 months choroidal neovascularisation diameter was stable; no leakage from active choroidal neovascularisation was seen in 76% (16/21) of eyes. After 12 months follow-up, increase in choroidal neovascularisation diameter was seen in 43% (9/21) of eyes and no leakage in 57% (12/21) of cases. The mean DBCVA significantly improved only after 3 months (p < 0.02). Significant decrease of mean foveal thickness was observed in each follow-ups (p < 0.01). The mfERG data from the macular region remained stable or improved slightly in some cases.
In our series of patients with the wet type of AMD after intravitreal injections of ranibizumab in 12 months follow-up, the reduction of foveal thickness was noted while DBCVA and the bioelectrical function from the macular region measured by the mfERG remained stable.
评估湿性年龄相关性黄斑变性（AMD）患者玻璃体内注射雷珠单抗前后的黄斑中心凹功能、视网膜循环及黄斑中心凹厚度。
研究组由21只眼（20例患者）因AMD导致的脉络膜新生血管（CNV）组成。纳入标准基于荧光素血管造影（FA）和远距离最佳矫正视力（DBCVA）——对数最小分辨角视力（log MAR）量表。每只眼每4周连续注射3次雷珠单抗，然后根据DBCVA和光学相干断层扫描（OCT）进行个体化再注射疗程，最长至12个月。在基线、3个月、6个月和12个月随访时，进行以下检查：DBCVA、多焦视网膜电图（mfERG）和OCT。此外，在治疗前、基线后3个月和12个月进行FA检查。
基线时，FA显示主要为微小隐匿性脉络膜新生血管——57%（12/21）的眼。3个月时脉络膜新生血管直径稳定；76%（16/21）的眼未见活动性脉络膜新生血管渗漏。随访12个月后，43%（9/21）的眼脉络膜新生血管直径增加，57%（12/21）的病例未见渗漏。平均DBCVA仅在3个月后显著改善（p < 0.02）。每次随访时均观察到平均黄斑中心凹厚度显著降低（p < 0.01）。黄斑区的mfERG数据在某些情况下保持稳定或略有改善。
在我们这组湿性AMD患者中，玻璃体内注射雷珠单抗12个月随访后，黄斑中心凹厚度降低，而DBCVA和通过mfERG测量的黄斑区生物电功能保持稳定。
